Adams Kendra 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CFO Kendra Adams Receives RSUs, Converts to Shares
What Happened
- Kendra Adams, Chief Financial Officer of C4 Therapeutics (CCCC), received a 240,000‑share RSU award on Feb 13, 2026 and had previously‑granted RSUs vest and convert to stock on Feb 13–14, 2026.
- The vesting/conversion produced 34,700 shares (3,750 on 2/13 and 30,950 on 2/14) acquired at $0.00 (these were RSU settlements). The company withheld 17,244 shares to satisfy tax withholding (1,863 on 2/13 and 15,381 on 2/14) at $1.89 per share, totaling about $32,591. Net new shares delivered to Adams = 17,456 shares.
- These transactions are compensation‑related (awards and RSU settlements), not open‑market purchases or discretionary sales.
Key Details
- Transaction dates/prices: 2/13/2026 (award of 240,000 RSUs; conversion of 3,750 RSUs @ $0.00; 1,863 shares withheld @ $1.89); 2/14/2026 (conversion of 30,950 RSUs @ $0.00; 15,381 shares withheld @ $1.89).
- Shares owned after transaction: not specified in the provided filing.
- Footnotes: F1 = 240,000 RSUs vest per schedule (120,000 vest in three equal annual installments beginning Feb 13, 2027; 120,000 vest in full on Feb 13, 2029 subject to performance). F2 = the converted shares came from earlier RSU grants reported in prior Forms 4. F3 = withheld shares were to satisfy tax withholding and do not represent an open‑market sale by the reporting person.
- Filing timeliness: Form 4 was filed Feb 18, 2026 for transactions on Feb 13–14, 2026. This appears to be a late filing (Form 4 is generally due within two business days), which delays public transparency.
Context
- Code meanings: A = Award/Grant; M = Exercise/conversion of a derivative (here, RSUs converting to shares); F = Shares withheld for tax obligations. The M entries reflect RSU settlement (no cash exercise price), not exercise of stock options requiring cash.
- For retail investors: these entries are routine executive compensation events (grant + RSU vesting and tax withholding). They indicate equity compensation being delivered, not an insider buying or publicly selling to express a market view.
Insider Transaction Report
Form 4
Adams Kendra
Chief Financial Officer
Transactions
- Award
Common Stock
[F1]2026-02-13+240,000→ 402,342 total - Exercise/Conversion
Common Stock
[F2]2026-02-13+3,750→ 402,342 total - Tax Payment
Common Stock
[F3]2026-02-13$1.89/sh−1,863$3,521→ 400,479 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+30,950→ 400,479 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−15,381$29,070→ 385,098 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Signature
/s/ Shagha Russell, Attorney-in-Fact|2026-02-18